(Q34632080)

English

Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

pharmacodynamics

1 reference

based on heuristic

inferred from title

1

object named as

C Twelves

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

author name string

W Scheithauer

2

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

J McKendrick

3

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

J-F Seitz

4

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

G Van Hazel

5

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

A Wong

6

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

E Díaz-Rubio

7

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

F Gilberg

8

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

J Cassidy

9

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

publication date

6 September 2011

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

23

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

1190-1197

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR366

21 January 2018

Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR366

21 January 2018

Adjuvant 5-fluorouracil and leucovorin with or without interferon alfa-2a in colon carcinoma: National Surgical Adjuvant Breast and Bowel Project protocol C-05.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR366

21 January 2018

Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR366

21 January 2018

Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR366

21 January 2018

Capecitabine as adjuvant treatment for stage III colon cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR366

21 January 2018

Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR366

21 January 2018

First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR366

21 January 2018

End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR366

21 January 2018

Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR366

21 January 2018

A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR366

21 January 2018

Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR366

21 January 2018

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR366

21 January 2018

Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR366

21 January 2018

Gefitinib in patients with advanced non-small cell lung cancer (NSCLC): the expanded access protocol experience at the University of Pennsylvania

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR366

21 January 2018

Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR366

21 January 2018

A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR366

21 January 2018

Potential regional differences for the tolerability profiles of fluoropyrimidines

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR366

21 January 2018

Identifiers

10.1093/ANNONC/MDR366

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34632080&oldid=2143632446"